Study Title and Description
Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.
Key Questions Addressed
|3||In adult renal transplants, how do immunosuppressive regimens designed to reduce or eliminate exposure to CNI toxicity compare with each other and with full-dose CNI regimens for health outcomes? AND How does the type of induction agent (including when no induction is used) and the use of concurrent immunosuppressive agents affect outcomes of regimens that reduce or eliminate CNI exposure?|
Primary Publication Information
|Title||Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.|
|Author||Budde K., Rath T., Sommerer C., Haller H., Reinke P., Witzke O., Suwelack B., Baeumer D., May C., Porstner M., Arns W.|
|Country||Department of Nephrology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Department of Nephrology and Transplantation Medicine, Westpfalz- Klinikum, Kaiserslautern, Department of Nephrology, Heidelberg University Hospital, Heidelberg, Department of Nephrology and Hypertensiology, Hannover Medical School, Hannover, Department of Transplantation, Division of Internal Medicine and Nephrology, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Department of Internal Medicine D, Transplant Nephrology, University of Münster, Münster, Novartis Pharma GmbH, Nuernberg, Department of Nephrology, Medical Clinic Köln-Merheim, Cologne, Germany, and APOLLO Study Group.|
Pubmed ID: 25512099
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Comparative Effectiveness of Regimens
Results & Comparisons
No Results found.